NCT04531098View on ClinicalTrials.gov

A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

March 2, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Sci-B-Vac-Lot B

Sci-B-Vac Lot B -10 μg of HBsAg, intramuscular injection of 10 μg/ml

BIOLOGICAL

Sci-B-Vac-Lot A

Sci-B-Vac Lot A - 10 μg of HBsAg, intramuscular injection of 10 μg/ml

BIOLOGICAL

Engerix-B

Engerix-B (hepatitis B vaccine (recombinant)) is indicated for active immunization against hepatitis B virus infection

Trial Locations (1)

Unknown

National Institute of Hygiene and Epidemiology (NIHE), Hanoi

All Listed Sponsors
lead

VBI Vaccines Inc.

INDUSTRY

NCT04531098 - A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults | Biotech Hunter | Biotech Hunter